Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; the references it cites are not checked yet.

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

Open access
Wu, Fanglong, Yang, Jin, Liu, Junjiang, Wang, Ye, Mu, Jingtian, Zeng, Qingxiang, Deng, Shuzhi, Zhou, Hongmei·2021·Signal Transduction and Targeted Therapy

Abstract

To flourish, cancers greatly depend on their surrounding tumor microenvironment (TME), and cancer-associated fibroblasts (CAFs) in TME are critical for cancer occurrence and progression because of their versatile roles in extracellular matrix remodeling, maintenance of stemness, blood vessel formation, modulation of tumor metabolism, immune response, and promotion of cancer cell proliferation, migration, invasion, and therapeutic resistance. CAFs are highly heterogeneous stromal cells and their crosstalk with cancer cells is mediated by a complex and intricate signaling network consisting of transforming growth factor-beta, phosphoinositide 3-kinase/AKT/mammalian target of rapamycin, mitogen-activated protein kinase, Wnt, Janus kinase/signal transducers and activators of transcription, epidermal growth factor receptor, Hippo, and nuclear factor kappa-light-chain-enhancer of activated B cells, etc., signaling pathways. These signals in CAFs exhibit their own special characteristics during the cancer progression and have the potential to be targeted for anticancer therapy. Therefore, a comprehensive understanding of these signaling cascades in interactions between cancer cells and CAFs is necessary to fully realize the pivotal roles of CAFs in cancers. Herein, in this review, we will summarize the enormous amounts of findings on the signals mediating crosstalk of CAFs with cancer cells and its related targets or trials. Further, we hypothesize three potential targeting strategies, including, namely, epithelial–mesenchymal common targets, sequential target perturbation, and crosstalk-directed signaling targets, paving the way for CAF-directed or host cell-directed antitumor therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-021-00641-0

Cites

Statistics

Figures

Fig. 1 Conversion from normal fibroblasts (NFs) to cancer-associated fibroblasts (CAFs). a Grow factors and cytokines such as transforming growth factor-beta 1 (TGF-β1), osteopontin (OPN), and IL-1β combined with their reporters in NFs, then activated the downstream effector including miRNAs and CD44, etc. to regulate the targeted gene expression of CAFs through TGF-β/Smads and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways. b Cancer-derived exosomes shuttling cargos such as miRNAs and lncRNAs transformed NFs to CAFs via the downstream signals including TGF-β/Smads, Janus kinase/signal transducers and activators of transcription (JAK/STAT), NF-κB and mitogen-activated protein kinase (MAPK) cascades. c NF-CAF conversion was driven by glucose metabolism reprogramming and hypoxia-inducible factor-1α (HIF-1α) signaling pathway was implicated in this glycolysis. d Changes in cellular homeostasis triggered the self-propelled conversion by regulating the cytoskeletal proteins activation and secreted phenotype through the JAK/STAT and p53 signaling pathways. Fli-1 leukemia integration 1, TCF12 transcription factor 12, SOCS1 suppressor of cytokine signaling 1, B4GALT3 β-1,4-galactosyltransferases III, IGF2R insulin-like growth factor 2 receptor, LPA lysophosphatidic acid, VDAC voltage-dependent anion channel, YAP1 Yes-associated protein 1, TEAD1 TEA domain transcription factor-1, SDF-1 stromal cell-derived factor-1, also known as CXCL12, EREG epiregulin, ROS reactive oxygen species
Fig. 1 Conversion from normal fibroblasts (NFs) to cancer-associated fibroblasts (CAFs). a Grow factors and cytokines such as transforming growth factor-beta 1 (TGF-β1), osteopontin (OPN), and IL-1β combined with their reporters in NFs, then activated the downstream effector including miRNAs and CD44, etc. to regulate the targeted gene expression of CAFs through TGF-β/Smads and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways. b Cancer-derived exosomes shuttling cargos such as miRNAs and lncRNAs transformed NFs to CAFs via the downstream signals including TGF-β/Smads, Janus kinase/signal transducers and activators of transcription (JAK/STAT), NF-κB and mitogen-activated protein kinase (MAPK) cascades. c NF-CAF conversion was driven by glucose metabolism reprogramming and hypoxia-inducible factor-1α (HIF-1α) signaling pathway was implicated in this glycolysis. d Changes in cellular homeostasis triggered the self-propelled conversion by regulating the cytoskeletal proteins activation and secreted phenotype through the JAK/STAT and p53 signaling pathways. Fli-1 leukemia integration 1, TCF12 transcription factor 12, SOCS1 suppressor of cytokine signaling 1, B4GALT3 β-1,4-galactosyltransferases III, IGF2R insulin-like growth factor 2 receptor, LPA lysophosphatidic acid, VDAC voltage-dependent anion channel, YAP1 Yes-associated protein 1, TEAD1 TEA domain transcription factor-1, SDF-1 stromal cell-derived factor-1, also known as CXCL12, EREG epiregulin, ROS reactive oxygen speciesCC BY · PubMed Central
Fig. 2 TGF-β signaling pathway-mediated crosstalk between CAFs and cancer cells. The canonical TGF-β signaling pathways consist of TGF-β/Activin/Nodal-Smads pathway and bone morphogenetic protein/growth differentiation factor/Müllerian-inhibiting substance (BMP/GDF/MIS)-Smads pathway. Noncanonical pathways represent those that activate TGF-βR, but induce no-Smads pathway. Within tumor microenvironment (TME), a large number of TGF-β protein secreted by cancer cells mediated the transformation of NFs into CAFs supporting cancer progression by activation TGF-β signaling pathway, particularly canonical pathway. Activated CAFs can be orchestrated by TME to maintain their status and promote their proliferation and migration. In turn, these adaptations would also be contributed to the formation of tumor-promoting TME. CAF-secreted factors regulated extracellular matrix (ECM) remodeling to accelerate cancer invasion and metastasis indirectly. On the other hand, most factors derived from CAFs can directly mediate intricate regulation on the cancer cells. Most proteins, such as ECM proteins, GDF, TGF-β, IL-11, and CXCL12, could activate the pathway of cancer cells to exert biological functions, including promoting cancer growth, migration, invasion, and metastasis, through receptor–ligand binding. Genetic information would also transfer from CAFs into cancer cells by extracellular vehicles. CAF-derived exosomal miR-93 and miR-423 would be endocytosed by cancer cells and then promoted cancer chemoresistance and radioresistance. FOXA1 forkhead box protein A1, MMP2 matrix metalloproteinase 2, GP130 glycoprotein 130, CTGF connective tissue growth factor, IDH3α isocitrate dehydrogenase-3α, CAV-1 caveolin-1
Fig. 2 TGF-β signaling pathway-mediated crosstalk between CAFs and cancer cells. The canonical TGF-β signaling pathways consist of TGF-β/Activin/Nodal-Smads pathway and bone morphogenetic protein/growth differentiation factor/Müllerian-inhibiting substance (BMP/GDF/MIS)-Smads pathway. Noncanonical pathways represent those that activate TGF-βR, but induce no-Smads pathway. Within tumor microenvironment (TME), a large number of TGF-β protein secreted by cancer cells mediated the transformation of NFs into CAFs supporting cancer progression by activation TGF-β signaling pathway, particularly canonical pathway. Activated CAFs can be orchestrated by TME to maintain their status and promote their proliferation and migration. In turn, these adaptations would also be contributed to the formation of tumor-promoting TME. CAF-secreted factors regulated extracellular matrix (ECM) remodeling to accelerate cancer invasion and metastasis indirectly. On the other hand, most factors derived from CAFs can directly mediate intricate regulation on the cancer cells. Most proteins, such as ECM proteins, GDF, TGF-β, IL-11, and CXCL12, could activate the pathway of cancer cells to exert biological functions, including promoting cancer growth, migration, invasion, and metastasis, through receptor–ligand binding. Genetic information would also transfer from CAFs into cancer cells by extracellular vehicles. CAF-derived exosomal miR-93 and miR-423 would be endocytosed by cancer cells and then promoted cancer chemoresistance and radioresistance. FOXA1 forkhead box protein A1, MMP2 matrix metalloproteinase 2, GP130 glycoprotein 130, CTGF connective tissue growth factor, IDH3α isocitrate dehydrogenase-3α, CAV-1 caveolin-1CC BY · PubMed Central
Fig. 3 PI3K/AKT/mTOR signaling pathway in CAFs and the crosstalk of CAFs with cancer cells. In the CAFs, by the receptor–ligand binding, activated phosphatidylinositol-3-kinase (PI3K) can phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), while miRNA-21 could attenuate the inhibition of phosphatase and tensin homolog (PTEN) on PIP3. As a result, PIP3 activated phosphoinositide-dependent kinase 1 (PDK1)/AKT signaling cascade to transfer the rapamycin target protein (mTOR) into the nuclei, subsequently regulating the expression of targeted genes associated with differentiation into CAFs and motility, etc. Notch signaling pathway was also involved in CAF differentiation via AKT signaling pathway. B7-H3 promoted AKT phosphorylation for proliferation in CAFs, while AKT phosphorylation was involved in the inhibitory effects on the migration mediated by GW4064. Similarly, CAF-derived HGF, IGF-2, IL-22, and CXCL5 can activate PI3K/AKT/mTOR signaling axis, while CXCL12 can inhibit PTEN. Nodal-induced activation of Smad2/3 could activate AKT phosphorylation and lncRNA UCA1 collaborated with mTOR. Consequently, CAF-mediated PI3K/AKT signaling pathway regulated the cell proliferation, migration, and stemness in cancer cells. FXR farnesoid X receptor, HGF hepatocyte growth factor, IGR insulin growth factor receptor, GPER G-protein-coupled estrogen receptor, EGFR epidermal growth factor receptor, VEGFR vascular endothelial growth factor, DAPT, N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, VCAM-1 vascular cell adhesion molecule-1, SPARC secreted protein acidic and rich in cysteine
Fig. 3 PI3K/AKT/mTOR signaling pathway in CAFs and the crosstalk of CAFs with cancer cells. In the CAFs, by the receptor–ligand binding, activated phosphatidylinositol-3-kinase (PI3K) can phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), while miRNA-21 could attenuate the inhibition of phosphatase and tensin homolog (PTEN) on PIP3. As a result, PIP3 activated phosphoinositide-dependent kinase 1 (PDK1)/AKT signaling cascade to transfer the rapamycin target protein (mTOR) into the nuclei, subsequently regulating the expression of targeted genes associated with differentiation into CAFs and motility, etc. Notch signaling pathway was also involved in CAF differentiation via AKT signaling pathway. B7-H3 promoted AKT phosphorylation for proliferation in CAFs, while AKT phosphorylation was involved in the inhibitory effects on the migration mediated by GW4064. Similarly, CAF-derived HGF, IGF-2, IL-22, and CXCL5 can activate PI3K/AKT/mTOR signaling axis, while CXCL12 can inhibit PTEN. Nodal-induced activation of Smad2/3 could activate AKT phosphorylation and lncRNA UCA1 collaborated with mTOR. Consequently, CAF-mediated PI3K/AKT signaling pathway regulated the cell proliferation, migration, and stemness in cancer cells. FXR farnesoid X receptor, HGF hepatocyte growth factor, IGR insulin growth factor receptor, GPER G-protein-coupled estrogen receptor, EGFR epidermal growth factor receptor, VEGFR vascular endothelial growth factor, DAPT, N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, VCAM-1 vascular cell adhesion molecule-1, SPARC secreted protein acidic and rich in cysteineCC BY · PubMed Central
Fig. 4 MAPK signaling pathway in CAFs and the crosstalk of CAFs with cancer cells. In CAFs, by E2 and G1, the EGFR/ERK signaling upregulated FASN expression for the metabolism of fatty acids. The PDGF-BB and SDF-1 could stimulate the higher invasive and migratory capability of CAFs via ERK1/2 phosphorylation. FA activated RAS upregulating SNAIL1 via ERK2 signaling, which mediated the fibrogenic response of CAFs. TIMP-1 enhanced CAF proliferation and migration and activated ERK1/2 signaling pathway in CAFs by the production of soluble factors. In the crosstalk between CAFs and cancer cells, CAF-derived EREG and POSTN could enhance the cancer cell proliferation and tumor growth by the downstream effector of ERK1/2. VCAM-1 and CAF-derived IL-32 increased the proliferation, invasion, metastasis, and EMT in cancer cells by activating p38/MAPK signaling pathway. Activated CXCL12/CXCR4 signal promoted EMT process through ERK/AKT-Twist1-MMP1 pathway. EPA decreased the expression of IL‑6 and VEGF secretion in CAFs by inhibition of ERK phosphorylation, thereof affecting angiogenesis. E2 17β-estradiol, G1 1-(4-(6-bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone, 1-[(3aS,4R,9bR-rel)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone, PDGF-BB platelet-derived growth factor-BB, FA focal adhesions, TIMP-1 tissue inhibitor of metalloproteinase-1, AP1 activating protein 1, FASN fatty acid synthase, SRF serum response factor, TCF ternary complex factor, POSTN periostin, EPA eicosapentaenoic acid, ECM extracellular matrix, EMT epithelial–mesenchymal transition
Fig. 4 MAPK signaling pathway in CAFs and the crosstalk of CAFs with cancer cells. In CAFs, by E2 and G1, the EGFR/ERK signaling upregulated FASN expression for the metabolism of fatty acids. The PDGF-BB and SDF-1 could stimulate the higher invasive and migratory capability of CAFs via ERK1/2 phosphorylation. FA activated RAS upregulating SNAIL1 via ERK2 signaling, which mediated the fibrogenic response of CAFs. TIMP-1 enhanced CAF proliferation and migration and activated ERK1/2 signaling pathway in CAFs by the production of soluble factors. In the crosstalk between CAFs and cancer cells, CAF-derived EREG and POSTN could enhance the cancer cell proliferation and tumor growth by the downstream effector of ERK1/2. VCAM-1 and CAF-derived IL-32 increased the proliferation, invasion, metastasis, and EMT in cancer cells by activating p38/MAPK signaling pathway. Activated CXCL12/CXCR4 signal promoted EMT process through ERK/AKT-Twist1-MMP1 pathway. EPA decreased the expression of IL‑6 and VEGF secretion in CAFs by inhibition of ERK phosphorylation, thereof affecting angiogenesis. E2 17β-estradiol, G1 1-(4-(6-bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone, 1-[(3aS,4R,9bR-rel)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone, PDGF-BB platelet-derived growth factor-BB, FA focal adhesions, TIMP-1 tissue inhibitor of metalloproteinase-1, AP1 activating protein 1, FASN fatty acid synthase, SRF serum response factor, TCF ternary complex factor, POSTN periostin, EPA eicosapentaenoic acid, ECM extracellular matrix, EMT epithelial–mesenchymal transitionCC BY · PubMed Central
Fig. 5 Crosstalk of different signaling pathways among CAFs, cancer cells, and immune cells. A reservoir of biological behaviors of CAFs, including CAFs generation, proliferation, ECM remodeling, and energy metabolism, etc. were regulated by several major signals like TGF-β and PI3K/AKT/mTOR signaling pathways. Importantly, CAF-mediated signaling pathways like JAK/STAT, Wnt, Hippo, MAPK, EGFR, and NF-κB signal were widely involved in cancer cells proliferation, stemness, invasion, migration, metastasis, angiogenesis, epithelial–mesenchymal transition (EMT) process, and therapeutic resistance. CAF-mediated signaling pathways did not always display with individual effects, but commonly crossed to each other to form a signaling network in cancer progression by the cross-connections such as STAT3, AKT, and YAP1. As the great source of cytokines, chemokines, and growth factors, CAF-secreted factors, including TGF-β1, IL-6, IL-8, CXCL1, CXCL12, and PGE2, etc., affect proliferation and activation of T cell, recruitment and activation of myeloid-derived suppressor cells (MDSCs), differentiation, and polarization of monocytes/macrophages, etc. PGE2 prostaglandin E2
Fig. 5 Crosstalk of different signaling pathways among CAFs, cancer cells, and immune cells. A reservoir of biological behaviors of CAFs, including CAFs generation, proliferation, ECM remodeling, and energy metabolism, etc. were regulated by several major signals like TGF-β and PI3K/AKT/mTOR signaling pathways. Importantly, CAF-mediated signaling pathways like JAK/STAT, Wnt, Hippo, MAPK, EGFR, and NF-κB signal were widely involved in cancer cells proliferation, stemness, invasion, migration, metastasis, angiogenesis, epithelial–mesenchymal transition (EMT) process, and therapeutic resistance. CAF-mediated signaling pathways did not always display with individual effects, but commonly crossed to each other to form a signaling network in cancer progression by the cross-connections such as STAT3, AKT, and YAP1. As the great source of cytokines, chemokines, and growth factors, CAF-secreted factors, including TGF-β1, IL-6, IL-8, CXCL1, CXCL12, and PGE2, etc., affect proliferation and activation of T cell, recruitment and activation of myeloid-derived suppressor cells (MDSCs), differentiation, and polarization of monocytes/macrophages, etc. PGE2 prostaglandin E2CC BY · PubMed Central
Fig. 6 CAF-mediated therapeutic resistance in anticancer treatment. a CAFs secreted dense desmoplastic matrix, including laminin A1, type IV collagen into the TME hindering the delivery of drugs, and increasing the resistance. b CAFs released regulatory molecules such as periostin, Nodal, EGF, IGF-2, and IL-6 or exosomes, which activated pro-survival signaling pathways, including proliferation, stemness, and apoptosis of cancer cells enhancing therapeutic resistance. c CAFs fed increased pyruvate, lactate, or GSSG to tumor cells by increasing energy supply and decreasing ROS. It also activated IGF-2 to increase autophagy via downstream pathways and the changes of metabolism in CAFs and tumor cells maintain the tumor survival in treatment. d CAFs released regulatory factors, including IGF-1, HGF, CXCL12, IL-6, and TGF-β1, to mediate EMT process through downstream ANAX2 and p38 pathways, subsequently increasing metastasis and resistance. TG2 tissue transglutaminase 2, LAMA1 laminin A1, Bcl-2 B cell lymphoma 2, Bax Bcl-2-associated X protein, Sox-2 SRY (sex-determining region Y)-box 2, TCA cycle tricarboxylic acid cycle, PP2A protein phosphatase 2A, CRM1 chromosomal region maintenance 1, GSSG glutathione disulfide, GSH glutathione, ANXA2 annexin A2
Fig. 6 CAF-mediated therapeutic resistance in anticancer treatment. a CAFs secreted dense desmoplastic matrix, including laminin A1, type IV collagen into the TME hindering the delivery of drugs, and increasing the resistance. b CAFs released regulatory molecules such as periostin, Nodal, EGF, IGF-2, and IL-6 or exosomes, which activated pro-survival signaling pathways, including proliferation, stemness, and apoptosis of cancer cells enhancing therapeutic resistance. c CAFs fed increased pyruvate, lactate, or GSSG to tumor cells by increasing energy supply and decreasing ROS. It also activated IGF-2 to increase autophagy via downstream pathways and the changes of metabolism in CAFs and tumor cells maintain the tumor survival in treatment. d CAFs released regulatory factors, including IGF-1, HGF, CXCL12, IL-6, and TGF-β1, to mediate EMT process through downstream ANAX2 and p38 pathways, subsequently increasing metastasis and resistance. TG2 tissue transglutaminase 2, LAMA1 laminin A1, Bcl-2 B cell lymphoma 2, Bax Bcl-2-associated X protein, Sox-2 SRY (sex-determining region Y)-box 2, TCA cycle tricarboxylic acid cycle, PP2A protein phosphatase 2A, CRM1 chromosomal region maintenance 1, GSSG glutathione disulfide, GSH glutathione, ANXA2 annexin A2CC BY · PubMed Central
Fig. 7 CAF-driven targeted therapies and alternative targeting avenues, including epithelial–mesenchymal common target (EMCT), sequential target perturbation (STP), and crosstalk-directed signaling target (CDST) for CAF-directed or host cell-directed antitumor therapy. a Besides the inhibition of NFs to CAFs, there are still two major ways to decrease the CAFs number in TME: (i) targeting specific markers of CAFs by monoclonal antibody (mAb), recombinant virus, anti-precursor cell to deplete CAFs; (ii) revert the activated CAFs to quiescent phenotype by retinoic acid (RA), angiotensin receptor blockers (ARBs), gold nanoparticle (GNP), etc. b Both simultaneous overexpression of the same molecular protein in CAFs and cancer cells like TGF-βRIII and NRG1 has the potential to be targeted as EMCT. c In the regard to CAF-mediated signaling pathways in crosstalk with cancer cells, CDST is targeting simultaneously two different components of one signaling cascade in cancer cells and CAFs, respectively, in which the trigger locating in the upstream of CAFs (Target I), while effector locating in the downstream of cancer cells (Target II). d EGFR-TKI targets the mut-EGFR in cancer cells, while EGFR is up-expressed in CAFs. STP on cancer cells and CAFs, targeting the EGFR in cancer cells firstly (Step①), then in CAFs (Step②), may promote NK cell function to enhance antitumor efficacy and also avoid the IGF-2-mediated chemoresistance after long-term treatment. Since there are different functions in cancer cells and CAFs, STP also aims at targeting CAFs to block the protumor effect firstly (Step①: such as targeting ECM remodeling to move the barrier for CD8+ T cell infiltration) and then aiming at cancer cells (Step②: such as performing PD-1/PD-L1 to antitumor immunotherapy) might obtain well therapeutic efficacy
Fig. 7 CAF-driven targeted therapies and alternative targeting avenues, including epithelial–mesenchymal common target (EMCT), sequential target perturbation (STP), and crosstalk-directed signaling target (CDST) for CAF-directed or host cell-directed antitumor therapy. a Besides the inhibition of NFs to CAFs, there are still two major ways to decrease the CAFs number in TME: (i) targeting specific markers of CAFs by monoclonal antibody (mAb), recombinant virus, anti-precursor cell to deplete CAFs; (ii) revert the activated CAFs to quiescent phenotype by retinoic acid (RA), angiotensin receptor blockers (ARBs), gold nanoparticle (GNP), etc. b Both simultaneous overexpression of the same molecular protein in CAFs and cancer cells like TGF-βRIII and NRG1 has the potential to be targeted as EMCT. c In the regard to CAF-mediated signaling pathways in crosstalk with cancer cells, CDST is targeting simultaneously two different components of one signaling cascade in cancer cells and CAFs, respectively, in which the trigger locating in the upstream of CAFs (Target I), while effector locating in the downstream of cancer cells (Target II). d EGFR-TKI targets the mut-EGFR in cancer cells, while EGFR is up-expressed in CAFs. STP on cancer cells and CAFs, targeting the EGFR in cancer cells firstly (Step①), then in CAFs (Step②), may promote NK cell function to enhance antitumor efficacy and also avoid the IGF-2-mediated chemoresistance after long-term treatment. Since there are different functions in cancer cells and CAFs, STP also aims at targeting CAFs to block the protumor effect firstly (Step①: such as targeting ECM remodeling to move the barrier for CD8+ T cell infiltration) and then aiming at cancer cells (Step②: such as performing PD-1/PD-L1 to antitumor immunotherapy) might obtain well therapeutic efficacyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 591 · Cited by 773

Research works printed but not linked: 3

  1. Nishio, M. et al. In Innovative Medicine: Basic Research and Development (eds Nakao, K., Minato, N. & Uemoto, S.) 79–94 (Springer, 2015).
  2. Wang, L. et al. Cancer‐associated fibroblasts contribute to cisplatin resistance by modulating ANXA 3 in lung cancer cells. Cancer Sci. 110, 1609–1620 (2019). · DOI
  3. Zhang, H. et al. Cancer-associated fibroblast–promoted LncRNADNM3OS confers radioresistance by regulating DNA damage response in esophageal squamous cell carcinoma. Clin. Cancer Res. 25, 1989–2000 (2019). · DOI · Paper page

Metadata

Authors
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H.
Affiliations
Sichuan University (CN)
Corresponding author
Zhou, Hongmei
Venue
Signal Transduction and Targeted Therapy
Published
2021-06-10
Volume
6
Issue
1
Pages
218-218
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3171648992
Cited by
773
References
591
Citations by year
2026: 141 · 2025: 225 · 2024: 168 · 2023: 144 · 2022: 80 · 2021: 14
FWCI
12.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81772898, 2021YFS0194, 82071124, 82002884)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
cancer-associated fibroblasts, tumor microenvironment, signaling pathways, targeted therapy, TGF-beta, PI3K/AKT/mTOR pathway, mitogen-activated protein kinase, Wnt signaling, JAK/STAT signaling, EGFR, Hippo signaling pathway, NF-κB, epithelial-mesenchymal transition, treatment resistance, extracellular matrix remodeling, cancer therapy
MeSH terms
Cancer-Associated Fibroblasts, Extracellular Matrix, Humans, Neoplasms, Signal Transduction, Transforming Growth Factor beta, Phosphatidylinositol 3-Kinases, Cell Proliferation, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. https://app.cochat.ai/papers/10.1038/s41392-021-00641-0
The paper
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021). Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00641-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.